U.S. News Room
September 18, 2021
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
Download
September 18, 2021
ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download
September 17, 2021
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers
Download
September 17, 2021
ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
Download